A new antibody treatment for active Sjögren's syndrome
Part of Immune system & allergy clinical trials.
This study tests a new medicine called ESG206, which is designed to calm the immune system and reduce the symptoms of Sjögren's syndrome. If you join, you may get this medicine or a placebo, and the study will see if it safely helps with things like dry eyes and dry mouth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with primary Sjögren's syndrome (not caused by another condition).
- Your Sjögren's is active, meaning you have symptoms like dry eyes, dry mouth, or fatigue that are affecting you now.
- You do not have other autoimmune diseases, like lupus or rheumatoid arthritis.
- You have not recently taken strong immune-suppressing medications (like certain biologics or high-dose steroids).
- You do not have serious infections, cancer, or unstable medical conditions, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is building a new model to help doctors treat primary Sjögren's syndrome using a combination of traditional Chinese medicine and Western medicine. It may help find better ways to manage your symptoms.
This study tests an investigational drug called RSLV-132 in women with Sjögren's disease to see if it can reduce symptoms like fatigue and dryness. You may join if you've been diagnosed in the last 30 years and have persistent symptoms.
This study tests an investigational drug called CM336 for people with active Sjögren's syndrome. It aims to see if the drug is safe and effective in reducing symptoms like joint pain and dryness when other treatments haven't worked well.
This study tests a new medicine called ICP-488 for people with primary Sjögren's syndrome. It may help reduce symptoms like dry eyes and dry mouth by calming the immune system. The trial lasts about 48 weeks and includes regular check-ups.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This study tests whether upadacitinib, a pill that reduces inflammation, can help people with Sjögren's syndrome. It aims to see if the drug can lower disease activity and improve symptoms.
Hear when a new Primary Sjögren Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.